Sanofi (EPA:SAN) has been given a €75.00 ($87.21) price target by stock analysts at Barclays in a research note issued to investors on Friday, Borsen Zeitung reports. The firm currently has a “sell” rating on the stock. Barclays‘s price target would indicate a potential downside of 9.78% from the company’s current price.
A number of other equities research analysts have also issued reports on SAN. HSBC set a €79.00 ($91.86) price target on Sanofi and gave the company a “neutral” rating in a research report on Wednesday, November 27th. Deutsche Bank set a €92.00 ($106.98) price objective on Sanofi and gave the stock a “buy” rating in a research report on Friday, November 1st. Morgan Stanley set a €90.00 ($104.65) target price on shares of Sanofi and gave the stock a “buy” rating in a research note on Monday, September 23rd. Bank of America set a €100.00 ($116.28) target price on shares of Sanofi and gave the company a “buy” rating in a report on Friday, September 13th. Finally, UBS Group set a €89.50 ($104.07) price target on shares of Sanofi and gave the stock a “buy” rating in a research note on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of €89.81 ($104.43).
Shares of SAN stock opened at €83.13 ($96.66) on Friday. The company has a 50 day moving average price of €83.28 and a 200 day moving average price of €78.75. Sanofi has a fifty-two week low of €63.09 ($73.36) and a fifty-two week high of €92.97 ($108.10).
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Further Reading: Monthly Dividend Stocks
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.